IN2009KN04568A - - Google Patents
Download PDFInfo
- Publication number
- IN2009KN04568A IN2009KN04568A IN4568KON2009A IN2009KN04568A IN 2009KN04568 A IN2009KN04568 A IN 2009KN04568A IN 4568KON2009 A IN4568KON2009 A IN 4568KON2009A IN 2009KN04568 A IN2009KN04568 A IN 2009KN04568A
- Authority
- IN
- India
- Prior art keywords
- viral
- enzymes
- metabolic
- animal models
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in 'suicide' of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93276907P | 2007-06-01 | 2007-06-01 | |
US3324308P | 2008-03-03 | 2008-03-03 | |
PCT/US2008/006959 WO2009023059A2 (en) | 2007-06-01 | 2008-06-02 | Treatment of viral infections by modulation of host cell metabolic pathways |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2009KN04568A true IN2009KN04568A (en) | 2015-08-28 |
Family
ID=40351337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4568KON2009 IN2009KN04568A (en) | 2007-06-01 | 2008-06-02 |
Country Status (10)
Country | Link |
---|---|
US (3) | US8158677B2 (en) |
EP (3) | EP2581081A3 (en) |
JP (1) | JP5616220B2 (en) |
KR (1) | KR20100031528A (en) |
CN (1) | CN101820757A (en) |
AU (1) | AU2008287542C1 (en) |
CA (1) | CA2687964A1 (en) |
IL (1) | IL202403A0 (en) |
IN (1) | IN2009KN04568A (en) |
WO (1) | WO2009023059A2 (en) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8748627B2 (en) * | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
US8735595B2 (en) * | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
US20090176796A1 (en) | 2007-04-27 | 2009-07-09 | Purdue Pharma L. P. | Trpv1 antagonists including amide substituent and uses thereof |
EP2581081A3 (en) * | 2007-06-01 | 2013-07-31 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
JP5638961B2 (en) | 2008-03-13 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | Inhibitors of BMP signaling pathway |
CN101869568A (en) * | 2009-04-27 | 2010-10-27 | 中国医学科学院基础医学研究所 | Use of autophagy (B-cell apoptosis) inhibitor |
WO2010144611A2 (en) * | 2009-06-10 | 2010-12-16 | 3-V Biosciences, Inc. | Antivirals that target transporters, carriers, and ion channels |
EP2641906B1 (en) | 2009-07-08 | 2015-04-22 | Dermira (Canada), Inc. | Tofa analogs useful in treating dermatological disorders or conditions |
US9168269B2 (en) | 2010-02-18 | 2015-10-27 | The Trustees Of Princeton University | Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals |
CN101892226A (en) * | 2010-03-11 | 2010-11-24 | 新乡医学院 | Small interfering RNA (siRNA) for restraining ACC gene expression of human adipocyte and expression vector and application thereof |
EP2566853B1 (en) | 2010-05-05 | 2017-01-25 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
WO2011140296A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Triazoles as inhibitors of fatty acid synthase |
EP2392327A1 (en) * | 2010-06-04 | 2011-12-07 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Use of orlistat for the anti-parasitic treatment of a parasitic disease |
WO2012031763A1 (en) * | 2010-09-08 | 2012-03-15 | Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh | Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection |
CN102462674B (en) * | 2010-11-04 | 2014-04-02 | 刘丽宏 | Application of curcumin and curcumin derivatives in preparation of drug and/or health care product for treating and preventing diseases related to human cytomegalovirus infection |
WO2012103524A2 (en) * | 2011-01-27 | 2012-08-02 | The Trustees Of Princeton University | Inhibitors of mtor kinasa as anti- viral agents |
JP2014510155A (en) * | 2011-04-06 | 2014-04-24 | ザ トラスティーズ オブ プリンストン ユニバーシティ | Antiviral combination therapy |
US20140024101A1 (en) * | 2011-04-08 | 2014-01-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for increasing the replication capacity of an influenza virus in cultured cells |
PE20141531A1 (en) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | TRPV1 ANTAGONISTS INCLUDING DIHYDROXI SUBSTITUTES AND THEIR USES |
CN103889953B (en) * | 2011-07-01 | 2016-06-08 | 巴鲁﹒S﹒布隆伯格研究所 | As the sulfonamides heterocyclic carbamate derivatives of anti-hepatitis b virus infected antivirotic |
WO2013158820A1 (en) * | 2012-04-19 | 2013-10-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating viral diseases |
CN104703601A (en) * | 2012-07-03 | 2015-06-10 | 格雷斯兰生物科技股份有限公司 | Compositions and methods for treating and inhibiting viral infections |
JP6542192B2 (en) | 2013-03-14 | 2019-07-10 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | BMP inhibitors and methods of use thereof |
BR112016004118A2 (en) | 2013-09-12 | 2017-10-17 | Pfizer | use of acetyl-coa carboxylase inhibitors for acne vulgaris treatment |
WO2015073774A1 (en) | 2013-11-14 | 2015-05-21 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis b infections |
WO2015154883A1 (en) * | 2014-04-11 | 2015-10-15 | Helmholtz-Zentrum für Infektionsforschung GmbH | Neosoraphens |
US10513521B2 (en) | 2014-07-15 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting BMP |
CN104188969A (en) * | 2014-08-13 | 2014-12-10 | 广州凯普生物科技有限公司 | Medicament for preventing and treating reproductive organ cancer and application thereof |
US10542961B2 (en) | 2015-06-15 | 2020-01-28 | The Research Foundation For The State University Of New York | System and method for infrasonic cardiac monitoring |
US20170050945A1 (en) * | 2015-07-24 | 2017-02-23 | Insmed Incorporated | Compositions and methods for the treatment of sarcoidosis |
CA3003477A1 (en) * | 2015-11-01 | 2017-05-04 | Glycobac, Llc | Virus-free cell lines and methods for obtaining same |
WO2017161208A1 (en) * | 2016-03-16 | 2017-09-21 | Juno Therapeutics, Inc. | Methods for determining dosing of a therapeutic agent and related treatments |
CN105794561B (en) * | 2016-03-23 | 2019-01-01 | 浙江省农业科学院 | Rape element azoles improves the application and method of Rice Resistance rice black-streaked dwarf virus disease |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Loop coil degron body for target protein degradation |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
KR101805394B1 (en) * | 2016-05-27 | 2017-12-06 | 전남대학교산학협력단 | Pharmaceutical composition for preventing or treating Calicivirus infection |
US10889555B2 (en) | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
AU2017275209C1 (en) * | 2016-05-31 | 2020-01-23 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
WO2017222951A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
EP3554258B1 (en) | 2016-12-15 | 2023-07-19 | Société des Produits Nestlé S.A. | Compositions and methods that modulate phosphorus or enzymes in a companion animal |
WO2018147472A1 (en) * | 2017-02-09 | 2018-08-16 | 学校法人慶應義塾 | Blood biomarker |
EP3609502A1 (en) * | 2017-04-12 | 2020-02-19 | Vertex Pharmaceuticals Incorporated | Combination therapies for treating influenza virus infection |
CA3079959A1 (en) * | 2017-10-27 | 2018-10-26 | Transfusion Health, Llc | Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene |
EP3876927A1 (en) * | 2018-11-08 | 2021-09-15 | Universita' Degli Studi di Torino | Strigolactones for use in preventing and/or treating infections caused by viruses of the herpesviridae family |
CN110506676B (en) * | 2019-08-23 | 2022-03-08 | 上海海洋大学 | ELOVL1 gene and application thereof |
CN110812357B (en) * | 2019-11-06 | 2022-09-23 | 山东省农业科学院奶牛研究中心 | Application of biapenem in preparation of medicine for preventing and treating bovine enterovirus infection |
CN111317737B (en) * | 2020-02-24 | 2023-02-17 | 南方医科大学 | ACCase inhibitor CP640184 as medicine for treating and/or preventing dengue virus infection and pharmaceutical application thereof |
WO2021216699A1 (en) * | 2020-04-21 | 2021-10-28 | Ned Biosystems, Inc. | Compositions and methods for treatment and prophylaxis of viral infections |
US11826382B2 (en) * | 2020-05-01 | 2023-11-28 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
FR3110398B1 (en) * | 2020-05-20 | 2022-06-03 | Centre Nat Rech Scient | Compounds for their use in the reactivation of HIV in latent cells infected with HIV |
WO2021252607A1 (en) * | 2020-06-12 | 2021-12-16 | Novomer, Inc. | Beta-propiolactone compounds and ring opened beta-propiolactone compounds and uses for same |
TW202221120A (en) * | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | Compositions and methods for the treatment of metabolic syndrome |
CN111920801A (en) * | 2020-09-18 | 2020-11-13 | 郑州大学第一附属医院 | Application of epigallocatechin gallate in preparing medicine for treating and/or preventing diseases caused by Ehrlich virus infection |
US20240000805A1 (en) * | 2020-12-14 | 2024-01-04 | Md Vault Llc | Methods and pharmaceutical compositions for the treatment and prophylaxis of microbial infectious diseases and associated inflammatory disorders and for the treatment and prophylaxis of aging and associated diseases |
CN113698285B (en) * | 2021-07-28 | 2023-02-10 | 浙江海洋大学 | Halogenated curcumin derivative, preparation method thereof and application thereof in aquatic product preservation |
CN114292851B (en) * | 2022-01-12 | 2023-08-08 | 徐州医科大学 | Interference sequence for inhibiting Cnr1 gene expression, shRNA lentiviral vector, construction method and application |
WO2023212718A2 (en) * | 2022-04-29 | 2023-11-02 | Cornell University | Methods of treating a virus infection and methods of inhibiting viral replication |
CN115006390B (en) * | 2022-06-27 | 2024-04-19 | 国药集团动物保健股份有限公司 | Virus attenuation preparation, preparation method and application thereof |
CN115282278A (en) * | 2022-07-13 | 2022-11-04 | 山东大学 | Application of cholesterol regulator as antigen presentation promoter in treatment of hepatitis B |
WO2024028914A1 (en) * | 2022-08-04 | 2024-02-08 | Np1 Srl | Pharmaceutical composition for the treatment and prevention of hpv |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4602099A (en) | 1973-04-02 | 1986-07-22 | Merrell Dow Pharmaceuticals Inc. | Antirhinovirus agents |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
JPS5612114B2 (en) | 1974-06-07 | 1981-03-18 | ||
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4109496A (en) | 1977-12-20 | 1978-08-29 | Norris Industries | Trapped key mechanism |
FR2425432A1 (en) | 1978-05-10 | 1979-12-07 | Boehringer Ingelheim Lab | Antibiotic and antifungal cerulenin derivs. - prepd. from a 5-sulphonyloxy 1,2-isopropylidene xylofuranose |
FR2457864A2 (en) | 1979-06-01 | 1980-12-26 | Boehringer Ingelheim Lab | Chiral synthesis for prepn. of cerulenin enantiomers - starting from 5,6-di:desoxy 1,2-O-isopropylidene-alpha-d-xylo-hex-5-eno:furanose |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (en) | 1980-06-06 | 1986-07-28 | Sankyo Co | METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4334913A (en) | 1981-03-31 | 1982-06-15 | Union Carbide Corporation | Substituted 3-hydroxy-2-cyclohexene-1-one compounds as sugar enhancers for plants |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
JPS611698A (en) * | 1984-06-12 | 1986-01-07 | Mitsubishi Chem Ind Ltd | Novel corticoid derivative and its preparation |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
WO1986003488A1 (en) | 1984-12-04 | 1986-06-19 | Sandoz Ag | Indene analogs of mevalonolactone and derivatives thereof |
US4735895A (en) | 1984-12-28 | 1988-04-05 | Oncotech, Inc. | Cancer susceptibility test |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5188830A (en) | 1987-03-27 | 1993-02-23 | Merck & Co., Inc. | Methods for thrombolytic therapy |
SE503210C2 (en) | 1987-05-22 | 1996-04-22 | Squibb & Sons Inc | Phosphorus-containing HMG-CoA-Reductase Inhibitor, New Intermediates and Methods |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
JP2569746B2 (en) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | Quinoline mevalonolactones |
NO177005C (en) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogous process for the preparation of substituted pyridines, as well as intermediates for use in the preparation |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP0358607A3 (en) | 1988-09-09 | 1990-10-31 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Macrocyclic lacton derivatives with a microbicidal activity |
US4958089A (en) | 1988-12-20 | 1990-09-18 | Gazelle Microcircuits, Inc. | High output drive FET buffer for providing high initial current to a subsequent stage |
US5190969A (en) * | 1988-12-20 | 1993-03-02 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | 2,3-epoxy derivatives as anti retrovital chemotherapeutic agents |
AU621434B2 (en) * | 1988-12-21 | 1992-03-12 | Merrell Dow Pharmaceuticals Inc. | Antiretroviral furan ketones |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
US5064856A (en) | 1989-07-31 | 1991-11-12 | Merck & Co., Inc. | Novel hmg-coa synthase inhibitors |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (en) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
DE4126999A1 (en) | 1991-08-16 | 1993-02-18 | Basf Ag | HERBICIDE AGENT, CONTAINING 3-AMINOBENZO (B) THIOPHENE AS ANTIDOTS |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
GB9209628D0 (en) | 1992-05-05 | 1992-06-17 | Smithkline Beecham Plc | Compounds |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
EP0672131B1 (en) | 1992-10-30 | 2003-12-17 | The General Hospital Corporation | A novel cell cycle control protein |
WO1994016693A1 (en) | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6069298A (en) | 1993-02-05 | 2000-05-30 | Regents Of The University Of Minnesota | Methods and an acetyl CoA carboxylase gene for conferring herbicide tolerance and an alteration in oil content of plants |
US6310034B1 (en) | 1993-05-21 | 2001-10-30 | Ut-Battelle, Llc | Agouti polypeptide compositions |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5614551A (en) * | 1994-01-24 | 1997-03-25 | The Johns Hopkins University | Inhibitors of fatty acid synthesis as antimicrobial agents |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
DK0861026T3 (en) | 1995-09-20 | 2003-04-22 | Basf Ag | Synergistic herbicidal mixtures containing cyclohexenone oximeters |
ATE303144T1 (en) | 1995-11-17 | 2005-09-15 | Univ Johns Hopkins | INHIBITION OF FATTY ACID SYNTHASE AS A MEANS OF REDUCING THE AMOUNT OF ADIPOCYTES |
US6124125A (en) | 1996-01-08 | 2000-09-26 | Trustees Of Dartmouth College | AMP activated protein kinase |
US6136964A (en) | 1996-03-19 | 2000-10-24 | Cell Therapeutics, Inc. | Mammalian lysophosphatidic acid acyltransferase |
US6300487B1 (en) | 1996-03-19 | 2001-10-09 | Cell Therapuetics, Inc. | Mammalian lysophosphatidic acid acyltransferase |
US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US20030163845A1 (en) | 1998-09-02 | 2003-08-28 | Pradip Mukerji | Elongase genes and uses thereof |
EP1147204A1 (en) | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
US20020016216A1 (en) | 1999-06-08 | 2002-02-07 | Kenji Kobayashi | Golf club |
US6383987B1 (en) | 1999-12-15 | 2002-05-07 | Basf Aktiengesellschaft | Cyclohexenone oxime ether/(glyphosates/gluphosinates) suspension concentrates |
US7078205B2 (en) | 2000-02-17 | 2006-07-18 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
DE60120427D1 (en) | 2000-08-25 | 2006-07-20 | Sloan Kettering Inst Cancer | RADICICOL AND MONOCILLIN AND ITS ANALOGS AND ITS APPLICATIONS |
US7704979B2 (en) | 2000-09-01 | 2010-04-27 | The University Of Tennessee Research Foundation | Materials and methods for the treatment or prevention of obesity |
HU230458B1 (en) | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Rna interference mediating small rna molecules |
GB0107510D0 (en) | 2001-03-26 | 2001-05-16 | Univ Bristol | New elongase gene and a process for the production of -9-polyunsaturated fatty acids |
DE10115938A1 (en) | 2001-03-30 | 2002-10-10 | Medigene Ag Ges Fuer Molekular | Process for the preparation of oxirane carboxylic acids and derivatives thereof |
US20080161256A1 (en) | 2001-05-18 | 2008-07-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US6482858B1 (en) * | 2001-06-20 | 2002-11-19 | Dallas L Clouatre | (−)-hydroxycitric acid for wound healing and immunomodulation |
ES2566561T3 (en) | 2001-07-12 | 2016-04-13 | University Of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
US20030144345A1 (en) * | 2001-07-27 | 2003-07-31 | Marcel Gubler | Treatment of metabolic diseases with soraphen derivatives |
US7291616B2 (en) | 2001-10-31 | 2007-11-06 | Cell Therapeutics, Inc. | Aryl triazines as LPAAT-β inhibitors and uses thereof |
US20030158156A1 (en) | 2001-11-21 | 2003-08-21 | Kimberly-Clark Worldwide, Inc. | Methods for inhibiting the production of TSST-1 |
WO2003072602A2 (en) | 2001-12-20 | 2003-09-04 | Cellzome Ag | Protein complexes and methods for their use |
US20050119251A1 (en) | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
EP1478437B1 (en) * | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Acc inhibitors |
PE20030968A1 (en) | 2002-02-28 | 2004-01-12 | Novartis Ag | DERIVATIVES OF 5-PHENYLTIAZOLE AS KINASE INHIBITORS |
CN101633650A (en) | 2002-07-01 | 2010-01-27 | 法斯根有限责任公司 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
KR20050111573A (en) | 2002-10-31 | 2005-11-25 | 파스젠, 엘엘씨. | A method for inhibiting cancer development by fatty acid synthase inhibitors |
US20060147947A1 (en) | 2002-12-04 | 2006-07-06 | Javier Apfeld | AMPK pathway components |
GB0305152D0 (en) | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
US6875781B2 (en) | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
EP1626711A4 (en) | 2003-05-09 | 2010-10-06 | Univ Pennsylvania | Compositions and methods for treating cancer |
US8609830B2 (en) | 2003-05-16 | 2013-12-17 | Merck Sharp & Dohme Corp. | Methods and compositions for RNA interference |
ES2568769T3 (en) | 2003-07-30 | 2016-05-04 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
EP1660671A4 (en) | 2003-08-04 | 2007-09-12 | Bayer Pharmaceuticals Corp | Methods for screening and identifying compounds |
GB0320197D0 (en) | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
JP4790619B2 (en) | 2003-10-27 | 2011-10-12 | ロゼッタ インファーマティクス エルエルシー | Method for designing siRNA for gene silencing |
AU2004292992A1 (en) | 2003-11-24 | 2005-06-09 | Georgia State University Research Foundation, Inc | Fused ring dicationic anti-protozoan agents and their prodrugs |
JP5290524B2 (en) | 2004-01-12 | 2013-09-18 | メルク セローノ ソシエテ アノニム | Thiazole derivatives and uses thereof |
WO2005102315A1 (en) | 2004-04-23 | 2005-11-03 | Magnachem International Laboratories, Inc. | Synthetic lactone formulations for pain control |
US7220729B2 (en) | 2004-05-10 | 2007-05-22 | Academia Sinica | Huntington's Disease Treatment |
US20060195938A1 (en) | 2004-06-15 | 2006-08-31 | Eva-Maria Franken | Polynucleotides encoding insect acetyl coenzyme-A carboxylase and uses thereof |
US7211423B2 (en) | 2004-07-23 | 2007-05-01 | Bristol-Myers Squibb Co. | Acetyl CoA carboxylase 2 sequences and methods |
US20060040003A1 (en) * | 2004-08-10 | 2006-02-23 | Alvin Needleman | Dietary supplement for supressing appetite, enhancing and extending satiety, improving glycemic control, and stimulant free |
FR2888816B1 (en) | 2005-07-20 | 2007-08-31 | Airbus France Sas | MONOLITHIC AUTO-RAIDI PANEL |
EP1996725B1 (en) | 2006-03-03 | 2011-05-18 | Université Paris Diderot - Paris 7 | Method for the electrochemical detection of target nucleic acid sequences |
EP2046333A4 (en) | 2006-07-24 | 2010-09-15 | Glaxosmithkline Llc | Thiozolidinedione derivatives as p13 kinase inhibitors |
EP2581081A3 (en) * | 2007-06-01 | 2013-07-31 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
TWI552751B (en) | 2011-06-20 | 2016-10-11 | H 朗德貝克公司 | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia |
-
2008
- 2008-06-02 EP EP20120178059 patent/EP2581081A3/en not_active Withdrawn
- 2008-06-02 IN IN4568KON2009 patent/IN2009KN04568A/en unknown
- 2008-06-02 WO PCT/US2008/006959 patent/WO2009023059A2/en active Application Filing
- 2008-06-02 EP EP20120178048 patent/EP2572712A3/en not_active Withdrawn
- 2008-06-02 US US12/156,517 patent/US8158677B2/en not_active Expired - Fee Related
- 2008-06-02 CA CA002687964A patent/CA2687964A1/en not_active Abandoned
- 2008-06-02 JP JP2010510373A patent/JP5616220B2/en not_active Expired - Fee Related
- 2008-06-02 EP EP08827478A patent/EP2166843A4/en not_active Withdrawn
- 2008-06-02 CN CN200880101544A patent/CN101820757A/en active Pending
- 2008-06-02 KR KR20097027678A patent/KR20100031528A/en not_active Application Discontinuation
- 2008-06-02 AU AU2008287542A patent/AU2008287542C1/en not_active Ceased
-
2009
- 2009-11-29 IL IL202403A patent/IL202403A0/en unknown
-
2012
- 2012-04-03 US US13/438,616 patent/US9029413B2/en not_active Expired - Fee Related
-
2015
- 2015-12-21 US US14/977,424 patent/US9757407B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2009023059A3 (en) | 2010-01-07 |
EP2581081A2 (en) | 2013-04-17 |
CN101820757A (en) | 2010-09-01 |
EP2572712A2 (en) | 2013-03-27 |
US9029413B2 (en) | 2015-05-12 |
US20130065850A1 (en) | 2013-03-14 |
CA2687964A1 (en) | 2009-02-19 |
US8158677B2 (en) | 2012-04-17 |
US20090239830A1 (en) | 2009-09-24 |
AU2008287542B2 (en) | 2014-07-31 |
US9757407B2 (en) | 2017-09-12 |
US20160346309A1 (en) | 2016-12-01 |
AU2008287542C1 (en) | 2015-01-22 |
JP2010538968A (en) | 2010-12-16 |
EP2572712A3 (en) | 2013-11-20 |
JP5616220B2 (en) | 2014-10-29 |
EP2166843A2 (en) | 2010-03-31 |
WO2009023059A2 (en) | 2009-02-19 |
EP2166843A4 (en) | 2010-08-11 |
KR20100031528A (en) | 2010-03-22 |
AU2008287542A1 (en) | 2009-02-19 |
IL202403A0 (en) | 2010-06-30 |
EP2581081A3 (en) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2009KN04568A (en) | ||
Lyn et al. | Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes | |
Gao et al. | Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect | |
Jhang et al. | Monosodium urate crystals trigger Nrf2-and heme oxygenase-1-dependent inflammation in THP-1 cells | |
Das et al. | Design and validation of novel chikungunya virus protease inhibitors | |
Eltahla et al. | Inhibitors of the hepatitis C virus polymerase; mode of action and resistance | |
Shi et al. | Oxidative mechanism of arsenic toxicity and carcinogenesis | |
Allison et al. | Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). | |
Plassmeyer et al. | Caspases and therapeutic potential of caspase inhibitors in moderate–severe SARS‐CoV‐2 infection and long COVID | |
Stapleford et al. | Viral polymerase-helicase complexes regulate replication fidelity to overcome intracellular nucleotide depletion | |
Masferrer et al. | Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain | |
Yaguchi et al. | Extracellular high K+ stimulates vesicular glutamate release from astrocytes by activating voltage‐dependent calcium channels | |
Kai et al. | Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment | |
Mohammadi-Bardbori et al. | Alternative electron acceptors: proposed mechanism of paraquat mitochondrial toxicity | |
Nguyenla et al. | Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells | |
Bergant et al. | Attenuation of SARS‐CoV‐2 replication and associated inflammation by concomitant targeting of viral and host cap 2'‐O‐ribose methyltransferases | |
Akula et al. | Where are we with understanding of COVID-19? | |
Vinken et al. | Characterization of spontaneous cell death in monolayer cultures of primary hepatocytes | |
Lacroix et al. | The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir | |
Adachi et al. | Assay systems for screening food and natural substances that have anti-hyperuricemic activity: uric acid production in cultured hepatocytes and purine bodies-induced hyperuricemic model mice | |
Ranade et al. | Inhibitors of methionyl-tRNA synthetase have potent activity against Giardia intestinalis trophozoites | |
Ma et al. | Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity | |
Wang et al. | Identification and therapeutic intervention of coactivated anaplastic lymphoma kinase, fibroblast growth factor receptor 2, and ephrin type‐A receptor 5 kinases in hepatocellular carcinoma | |
Jiang et al. | Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor | |
BRPI0515161A (en) | phenoxazinone-derived enzymatic substrates and their use as a developer in the detection of peptidase activity microorganisms |